Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Treatment Option At The Sarah Cannon Cancer Center Provides Hope For Inoperable Tumors
The Sarah Cannon Cancer Center (SCCC) at Centennial Medical Center last week began treating patients with a new non-invasive weapon in the battle against cancer. The Sarah Cannon Cancer Center is the first and only cancer center in Middle Tennessee to offer image-guided robotic stereotactic radiosurgery.

AARP On Medicare Trustees Report: "Medicare's Accelerating Insolvency. Will Only Be Fixed By Comprehensive Reform In 2009."
AARP Executive Vice President John Rother issued the
News of the day
News From GP Conference, UK
GPs have warned that the reorganisation of health visitor services is putting children at risk and underlined the importance of them remaining in practice based teams. The call came at the Annual GPs Conference being held in London.
Sexual Health

Dynavax Awarded Grant To Support Development Of TLR Inhibitors In Skin Diseases

Dynavax Technologies Corporation (Nasdaq:DVAX) announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID). This grant will support the preclinical development of Dynavax"s first-in-class oligonucleotide-based Toll-like Receptor (TLR) inhibitors for use in inflammatory skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis. This new two-year $700,000 grant is in addition to a $1.8 million grant awarded in 2008. "In addition to validating our proprietary technology, this new grant supports the preclinical studies for our TLR inhibitors, which represent a novel therapeutic approach for the treatment of inflammatory skin disorders," commented Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer of Dynavax Technologies. "Grant funding and partnerships with leading pharmaceutical companies help us advance the development of our TLR-based products targeting significant unmet medical needs." For more information about Dynavax"s TLR inhibitor program, visit here. Dynavax Technologies Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009